Vyvgart 1 000 mg solution for injection
Sponsors
Argenx, Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
Conditions
Autoimmune dementiaGeneralized Myasthenia Gravis
Phase 2
A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
RecruitingCTIS2023-507379-23-00
Start: 2022-08-18Target: 19Updated: 2025-12-03
ARGX-113-2207: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of
Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis
RecruitingCTIS2023-506159-12-00
Start: 2024-09-06Target: 11Updated: 2025-11-18
A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem)
Not yet recruitingCTIS2023-510216-39-00
Target: 69Updated: 2025-06-17